Cargando…

Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials

Patients with cirrhosis who develop tense ascites and hepatorenal syndrome have a very high mortality and present a management challenge. Current debate stems from a lack of studies evaluating changes in effective arterial blood volume following paracentesis or targeting fluid replacement with appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mookerjee, Rajeshwar P, Jalan, Rajiv
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447551/
https://www.ncbi.nlm.nih.gov/pubmed/18394181
http://dx.doi.org/10.1186/cc6804
_version_ 1782156964717920256
author Mookerjee, Rajeshwar P
Jalan, Rajiv
author_facet Mookerjee, Rajeshwar P
Jalan, Rajiv
author_sort Mookerjee, Rajeshwar P
collection PubMed
description Patients with cirrhosis who develop tense ascites and hepatorenal syndrome have a very high mortality and present a management challenge. Current debate stems from a lack of studies evaluating changes in effective arterial blood volume following paracentesis or targeting fluid replacement with appropriate vascular physiological measures to ensure no paracentesis-related circulatory dysfunction. The study by Umgelter and colleagues addresses a goal-directed approach to fluid management in hepatorenal syndrome and raises several mechanistic questions, the answers to which are likely to improve our understanding of the pathophysiology in hepatorenal syndrome and to guide future management.
format Text
id pubmed-2447551
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24475512008-07-10 Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials Mookerjee, Rajeshwar P Jalan, Rajiv Crit Care Commentary Patients with cirrhosis who develop tense ascites and hepatorenal syndrome have a very high mortality and present a management challenge. Current debate stems from a lack of studies evaluating changes in effective arterial blood volume following paracentesis or targeting fluid replacement with appropriate vascular physiological measures to ensure no paracentesis-related circulatory dysfunction. The study by Umgelter and colleagues addresses a goal-directed approach to fluid management in hepatorenal syndrome and raises several mechanistic questions, the answers to which are likely to improve our understanding of the pathophysiology in hepatorenal syndrome and to guide future management. BioMed Central 2008 2008-03-19 /pmc/articles/PMC2447551/ /pubmed/18394181 http://dx.doi.org/10.1186/cc6804 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Commentary
Mookerjee, Rajeshwar P
Jalan, Rajiv
Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title_full Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title_fullStr Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title_full_unstemmed Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title_short Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
title_sort towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447551/
https://www.ncbi.nlm.nih.gov/pubmed/18394181
http://dx.doi.org/10.1186/cc6804
work_keys_str_mv AT mookerjeerajeshwarp towardsgoaldirectedtherapyofhepatorenalsyndromewehavethetoolsbutweneedthetrials
AT jalanrajiv towardsgoaldirectedtherapyofhepatorenalsyndromewehavethetoolsbutweneedthetrials